1. |
中国高血压防治指南修订委员会. 中国高血压防治指南2010[J]. 中华高血压杂志, 2011, 19(8):701-743.
|
2. |
Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension:the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2013, 34(28):2159-2219.
|
3. |
James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults:report from the panel members appointed to the Eighth Joint National Committee (JNC 8)[J]. JAMA, 2014, 311(5):507-520.
|
4. |
Sever P. New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society[J]. J Renin Angiotensin Aldosterone Syst, 2006, 7(2):61-63.
|
5. |
刘国树. β-受体阻滞剂在高血压治疗中的争论再评价[J]. 中国药物应用与监测, 2011, 8(4):195-199.
|
6. |
中华医学会心血管病学分会, 中华心血管病杂志编辑委员. β肾上腺素能受体阻滞剂在心血管疾病应用专家共识[J]. 中华心血管病杂志, 2009, 37(3):195-209.
|
7. |
Panjabi S, Lacey M, Bancroft T, et al. Treatment adherence, clinical outcomes, and economics of triple-drug therapy in hypertensive patients[J]. J Am Soc Hypertens, 2013, 7(1):46-60.
|
8. |
Baser O, Andrews LM, Wang L, et al. Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy[J]. J Med Econ, 2011, 14(5):576-583.
|
9. |
Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance:a meta-analysis[J]. Am J Med, 2007, 120(8):713-719.
|
10. |
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic:the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)[J]. JAMA, 2002, 288(23):2981-2997.
|
11. |
Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus:progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group[J]. JAMA, 1999, 281(21):2005-2012.
|
12. |
Hovater MB, Jaimes EA. Optimizing combination therapy in the management of hypertension:the role of the aliskiren, amlodipine, and hydrochlorothiazide fixed combination[J]. Integr Blood Press Control, 2013, 6:59-67.
|
13. |
Lacourcière Y, Poirier L, Hebert D, et al. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension:an 8-week, randomized, double-blind, parallel-group trial[J]. Clin Ther, 2005, 27(7):1013-1021.
|
14. |
Zhu DL, Gao PJ, Liu SW, et al. Efficacy and tolerability of a single-pill combination of telmisartan/hydrochlorothiazide 80/25 mg in Chinese and Korean patients with moderate to severe hypertension:a subgroup analysis of a randomized, double-blind, active-controlled trial[J]. Chin Med J, 2013, 126(21):4072-4077.
|
15. |
Ruilope LM, Malacco E, Khder Y, et al. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors:the VAST study[J]. Clin Ther, 2005, 27(5):578-587.
|
16. |
Zhu D, Gao P, Yagi N, et al. Efficacy and tolerability of telmisartan plus amlodipine in Asian patients not adequately controlled on either monotherapy or on low-dose combination therapy[J]. Int J Hypertens, 2014:475480.
|
17. |
Neldam S, Edwards C, Lang M, et al. Long-term tolerability and efficacy of single-pill combinations of telmisartan 40-80 mg plus amlodipine 5 or 10 mg in patients whose blood pressure was not initially controlled by amlodipine 5-10 mg:Open-Label, Long-Term Follow-Ups of the TEAMSTA-5 and TEAMSTA-10 studies[J]. Curr Ther Res Clin Exp, 2012, 73(1/2):65-84.
|
18. |
Lacourcière Y, Neutel JM, Schumacher H. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension:pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials[J]. Clin Ther, 2005, 27(11):1795-1805.
|
19. |
Neldam S, Lang M, Jones R, et al. Telmisartan and amlodipine single-pill combinations vs amlodipine monotherapy for superior blood pressure lowering and improved tolerability in patients with uncontrolled hypertension:results of the TEAMSTA-5 study[J]. J Clin Hypertens (Greenwich), 2011, 13(7):459-466.
|
20. |
Zhu DL, Bays H, Gao P, et al. Efficacy and tolerability of initial therapy with single-pill combination telmisartan/hydrochlorothiazide 80/25 mg in patients with grade 2 or 3 hypertension:a multinational, randomized, double-blind, active-controlled trial[J]. Clin Ther, 2012, 34(7):1613-1624.
|